帕金森病：安坦与息宁联用，反应更佳。

Parkinson's disease: Cogentin with Sinemet, a better response.

Tourtellotte W W, Potvin A R, Syndulko K, Hirsch S B, Gilden E R, Potvin J H, Hansch E C

Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(1):51-5. doi: 10.1016/s0364-7722(82)80107-0.

Abstract

A randomized, placebo controlled, double-blind cross-over study was conducted to evaluate the clinical efficacy of the anticholinergic agent, benztropine mesylate (CogentinR) in 29 patients with mild to moderate, idiopathic Parkinson disease. 2. Patients were maintained on a stable, therapeutically optimal dosage and schedule of levadopa-carbidopa (Sinemet) throughout the study. 3. Both the neurologist's and the patient's global assessments of treatment efficacy indicated that Sinemet plus benztropine mesylate resulted in significantly greater improvement than Sinemet plus placebo. 4. Qualitative and quantitative evaluations of relevant neurologic functions showed small, but statistically significant improvements for rigidity, finger tapping speed and activities of daily living in patients during the Sinemet plus benztropine mesylate treatment period. 5. At the completion of the study 16 patients chose to continue taking benztropine mesylate as an adjuvant to Sinemet. 6. No important adverse side effects occurred during the study.

摘要

开展了一项随机、安慰剂对照、双盲交叉研究，以评估抗胆碱能药物甲磺酸苯扎托品（安坦）对29例轻至中度特发性帕金森病患者的临床疗效。2. 在整个研究过程中，患者维持左旋多巴 - 卡比多巴（息宁）稳定、治疗最优剂量和给药方案。3. 神经科医生和患者对治疗效果的整体评估均表明，左旋多巴 - 卡比多巴加甲磺酸苯扎托品比左旋多巴 - 卡比多巴加安慰剂带来的改善显著更大。4. 相关神经功能的定性和定量评估显示，在左旋多巴 - 卡比多巴加甲磺酸苯扎托品治疗期间，患者的僵硬程度、手指敲击速度和日常生活活动有小幅但具有统计学意义的改善。5. 研究结束时，16名患者选择继续服用甲磺酸苯扎托品作为左旋多巴 - 卡比多巴的辅助药物。6. 研究期间未出现重要的不良副作用。